Relation of Beta-Blocker-Induced Heart Rate Lowering and Cardioprotection in Hypertension

Department of Medicine, Division of Cardiology, St Luke's Roosevelt Hospital, Columbia University College of Physicians and Surgeons, New York, New York 10019, USA.
Journal of the American College of Cardiology (Impact Factor: 16.5). 10/2008; 52(18):1482-9. DOI: 10.1016/j.jacc.2008.06.048
Source: PubMed


The purpose of this study was to evaluate the role of heart rate reduction with beta-blockers on the risk of cardiovascular events in patients with hypertension.
Resting heart rate has been shown to be a risk factor for cardiovascular morbidity and mortality in the general population and in patients with heart disease such as hypertension, myocardial infarction, and heart failure. Conversely, pharmacological reduction of heart rate is beneficial for patients with heart disease. However, the role of pharmacological reduction of heart rate using beta-blockers in preventing cardiovascular events in patients with hypertension is not known.
We conducted a MEDLINE/EMBASE/CENTRAL database search of studies from 1966 to May 2008. We included randomized controlled trials that evaluated beta-blockers as first-line therapy for hypertension with follow-up for at least 1 year and with data on heart rate. We extracted the baseline characteristics, the blood pressure response, heart rate at the baseline and end of trial, and cardiovascular outcomes from each trial.
Of 22 randomized controlled trials evaluating beta-blockers for hypertension, 9 studies reported heart rate data. The 9 studies evaluated 34,096 patients taking beta-blockers against 30,139 patients taking other antihypertensive agents and 3,987 patients receiving placebo. Paradoxically, a lower heart rate (as attained in the beta-blocker group at study end) was associated with a greater risk for the end points of all-cause mortality (r = -0.51; p < 0.0001), cardiovascular mortality (r = -0.61; p < 0.0001), myocardial infarction (r = -0.85; p < 0.0001), stroke (r = -0.20; p = 0.06), or heart failure (r = -0.64; p < 0.0001). The same was true when the heart rate difference between the 2 treatment modalities at the end of the study was compared with the relative risk reduction for cardiovascular events.
In contrast to patients with myocardial infarction and heart failure, beta-blocker-associated reduction in heart rate increased the risk of cardiovascular events and death for hypertensive patients.

Download full-text


Available from: Sripal Bangalore, Jan 22, 2014
  • Source
    • "Diuretics are used to remove excessive water and salt from the body through urine with a view to reducing blood pressure (Fuchs, 2001). Beta-blockers bind to the beta receptors in heart muscle and reduce the tissue stress stimulated by the hormone adrenaline (Bangalore, Sawhney & Messerli, 2008). ACE inhibitors act by inhibiting the ACE that reduces the activity of the reninangiotensin-aldosterone system (RAAS). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Hypertension is a multi-aetiological, chronic pathophysiology that leads to multi-organ dysfunctions like cardiovascular diseases, strokes, and renal complications. Synthetic anti-hypertensive drugs have been blamed for side effects of various sorts. Thus, the search for natural, safe, and food-based anti-hypertensive agents has gained momentum. Mushrooms, abundant in bio-active components, had been recognized for its use as therapeutics in alternative and complementary medicine as well as functional food. In the present article, the potential of both culinary and edible-turned-medicinal mushrooms is reviewed with respect to their anti-hypertensive effects along with the respective bio-component’s mode of action.
    Trends in Food Science & Technology 07/2014; 39(2). DOI:10.1016/j.tifs.2014.06.002 · 4.65 Impact Factor
  • Source
    • "Subsequently, this leads to a further elevation in SBP and a decrease in DBP, which exacerbates pulse pressure even more. Although it was thought that lowering heart rate is associated with a positive effect on outcome, this assumption has not held true.55 "
    [Show abstract] [Hide abstract]
    ABSTRACT: Treatment of hypertension in the elderly is expected to become more complex in the coming decades. Based on the current landscape of clinical trials, guideline recommendations remain inconclusive. The present review discusses the latest evidence derived from studies available in 2013 and investigates optimal blood pressure (BP) and preferred treatment substances. Three common archetypes are discussed that hamper the treatment of hypertension in the very elderly. In addition, this paper presents the current recommendations of the NICE 2011, JNC7 2013-update, ESH/ESC 2013, CHEP 2013, JNC8 and ASH/ISH guidelines for elderly patients. Advantages of the six main substance classes, namely diuretics, beta-blockers (BBs), calcium channel blockers (CCBs), angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), and direct renin inhibitors (DRIs) are discussed. Medical and economic implications of drug administration in the very elderly are presented. Avoidance of treatment-related adverse effects has become increasingly relevant. Current substance classes are equally effective, with similar effects on cardiovascular outcomes. Selection of substances should therefore also be based on collateral advantages of drugs that extend beyond BP reduction. The combination of ACEIs and diuretics appears to be favorable in managing systolic/diastolic hypertension. Diuretics are a preferred and cheap combination drug, and the combination with CCBs is recommended for patients with isolated systolic hypertension. ACEIs and CCBs are favorable for patients with dementia, while CCBs and ARBs imply substantial cost savings due to high adherence.
    Clinical Interventions in Aging 03/2014; 9:459-475. DOI:10.2147/CIA.S40154 · 2.08 Impact Factor
  • Source
    • "The aforementioned meta-analysis conducted by Bangalore et al. demonstrated an inverse relationship between heart rate and cardiovascular events in subjects with heart rates under 70 bpm, and no study until the current date has examined the relationship between the heart rate and the risk for cardiovascular events in cases receiving beta-blocker treatment with heart rates over 70 bpm. Furthermore, atenolol was used in more than 80% of the study subjects of the meta-analysis conducted by Bangalore et al. [35]. Thus, no study has examined the association between the reduction in heart rate and the increased risk of cardiovascular events by the treatment with beta-blockers other than atenolol. "
    [Show abstract] [Hide abstract]
    ABSTRACT: This minireview provides current summaries of beta-blocker use in the management of hypertension and/or chronic kidney disease. Accumulated evidence suggests that atenolol is not sufficiently effective as a primary tool to treat hypertension. The less-than-adequate effect of beta-blockers in lowering the blood pressure and on vascular protection, and the unfavorable effects of these drugs, as compared to other antihypertensive agents, on the metabolic profile have been pointed out. On the other hand, in patients with chronic kidney disease, renin-angiotensin system blockers are the drugs of first choice for achieving the goal of renal protection. Recent studies have reported that vasodilatory beta-blockers have adequate antihypertensive efficacy and less harmful effects on the metabolic profile, and also exert beneficial effects on endothelial function and renal protection. However, there is still not sufficient evidence on the beneficial effects of the new beta-blockers.
    International Journal of Hypertension 01/2014; 2014:919256. DOI:10.1155/2014/919256
Show more